文献速递浆细胞疾病

Belantamab mafodotin联合硼替佐米和地塞米松对比达雷妥尤单抗联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤的患者报告结局(DREAMM-7):一项3期、开放标签、随机对照试验的结果

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
PubMed 文献 · Lancet Haematol · 2025-07-15

DREAMM-7研究在20个国家142家医院纳入494例复发或难治性多发性骨髓瘤患者,随机1:1接受belantamab mafodotin联合硼替佐米和地塞米松或达雷妥尤单抗联合硼替佐米和地塞米松治疗。两组EORTC QLQ-C30和QLQ-MY20平均评分随时间保持稳定,多数患者报告整体健康状况、角色功能、躯体功能及疾病症状稳定或改善。作者认为患者报告的健康相关生活质量总体维持或改善,结合既往临床获益,支持belantamab mafodotin作为复发或难治性多发性骨髓瘤潜在新标准治疗。

要点

  • 两组EORTC QLQ-C30和QLQ-MY20平均评分随时间保持稳定。
  • 多数患者在多个时间点报告整体健康、角色功能、躯体功能和疾病症状稳定或改善。
  • 大多数患者报告治疗副作用困扰程度为「完全没有」「有一点」或「有一些」。

核心结论

  • Belantamab mafodotin联合硼替佐米和地塞米松治疗期间健康相关生活质量总体维持或改善。
  • 作者认为该结果结合既往报告的临床获益,支持belantamab mafodotin作为复发或难治性多发性骨髓瘤的潜在新标准治疗。

研究设计与样本

  • 3期、开放标签、随机对照试验,在20个国家142家医院进行。
  • 纳入18岁及以上、接受过至少一线治疗且末次治疗后进展、ECOG体能状态0-2的复发或难治性多发性骨髓瘤患者。
  • 共494例患者纳入意向治疗人群,随机1:1分配至belantamab mafodotin组(n=243)或达雷妥尤单抗组(n=251)。
  • 患者报告结局为次要和探索性目标,采用EORTC QLQ-C30、EORTC QLQ-MY20、PRO-CTCAE、OSDI、FACT-GP5和EQ-5D VAS评估,结果用描述性统计汇总,最小二乘均值变化采用基于限制性最大似然法的混合模型估计。

主要发现

  • 截至数据截止,中位随访28.2个月(IQR 14.6-31.4)。
  • 两组EORTC QLQ-C30和QLQ-MY20平均评分随时间保持稳定。
  • 在各时间点,belantamab mafodotin组报告整体健康状况/生活质量稳定或改善的患者为64/115(56%)至85/114(75%),达雷妥尤单抗组为105/207(51%)至156/240(65%)。
  • 在各时间点,belantamab mafodotin组报告角色功能稳定或改善的患者为103/196(53%)至77/114(68%),达雷妥尤单抗组为99/197(50%)至92/134(69%)。
  • 在各时间点,belantamab mafodotin组报告躯体功能稳定或改善的患者为132/201(66%)至101/131(77%),达雷妥尤单抗组为115/197(58%)至102/134(76%)。

关键数值与推荐

  • EORTC QLQ-C30整体健康状况/生活质量稳定或改善:belantamab mafodotin组64/115(56%)至85/114(75%),达雷妥尤单抗组105/207(51%)至156/240(65%)。
  • EORTC QLQ-C30角色功能稳定或改善:belantamab mafodotin组103/196(53%)至77/114(68%),达雷妥尤单抗组99/197(50%)至92/134(69%)。
  • EORTC QLQ-C30躯体功能稳定或改善:belantamab mafodotin组132/201(66%)至101/131(77%),达雷妥尤单抗组115/197(58%)至102/134(76%)。
  • EORTC QLQ-MY20疾病症状域稳定或改善:belantamab mafodotin组79/109(72%)至95/115(83%),达雷妥尤单抗组126/190(66%)至164/221(74%)。
  • FACT-GP5报告对治疗副作用困扰为「完全没有」「有一点」或「有一些」:belantamab mafodotin组155/202(77%)至79/82(96%),达雷妥尤单抗组155/181(86%)至60/60(100%)。

临床怎么用

  • 作者认为,结合既往报告的临床获益,该患者报告结局结果支持belantamab mafodotin作为复发或难治性多发性骨髓瘤的潜在新标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Belantamab mafodotin, bortezomib, and dexamethasone showed significant progression-free survival benefit compared with daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma in the phase 3 DREAMM-7 study. We aimed to evaluate the effect of belantamab mafodotin, bortezomib, and dexamethasone compared with daratumumab, bortezomib, and dexamethasone on health-related quality of life (HRQOL) using various patient-reported outcomes in patients who participated in DREAMM-7. METHODS: This phase 3, open-label, randomised controlled trial, done at 142 hospitals in 20 countries included adult patients aged 18 years or older with relapsed or refractory multiple myeloma who received at least one previous line of therapy and progressed during or after their most recent treatment and had an Eastern Cooperative Oncology Group performance status of 0 to 2. Eligible patients were randomly assigned (1:1) by a central interactive response technology system to receive intravenous belantamab mafodotin (2·5 mg/kg once on day 1 of each 21-day cycle) or intravenous daratumumab (16 mg/kg once a week in cycles 1-3, every 3 weeks in cycles 4-8, and every 4 weeks in cycle 9 and beyond). Patients in both treatment groups also received subcutaneous bortezomib (1·3 mg/m2 on days 1, 4, 8, and 11 of 21-day cycles) and oral or intravenous dexamethasone (20 mg on the day of and day after bortezomib administration) for the first 8 cycles. Treatment continued until progressive disease, unacceptable toxic effects, withdrawal of consent, or death (whichever occurred first). Patient-reported outcomes were secondary and exploratory objectives. Secondary patient-reported outcome endpoints were change from baseline in HRQOL, as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLQ-MY20, and maximum postbaseline score for each item attribute on the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Exploratory patient-reported outcome endpoints included changes from baseline in symptoms and related effects as measured by Ocular Surface Disease Index (OSDI), change from baseline in FACT-GP5 score, and change from baseline in the EQ-5D VAS. EORTC QLQ-C30, EORTC QLQ-MY20, and FACT-GP5 scores were analysed in the intention-to-treat population, and PRO-CTCAE and OSDI vision-related functioning scores were analysed in the safety population (patients who received at least one dose of treatment). Results were summarised using descriptive statistics. Least-squares mean changes from baseline were estimated using a restricted maximum likelihood-based mixed model. This study was registered with ClinicalTrials.gov, NCT04246047, and is ongoing. FINDINGS: Between May 7, 2020, and June 28, 2021, 494 patients were included in the intention-to-treat population of the DREAMM-7 study (median follow-up 28·2 months, IQR 14·6-31·4) and were randomly assigned to either belantamab mafodotin, bortezomib, and dexamethasone (n=243) or daratumumab, bortezomib, and dexamethasone (n=251). 222 (45%) of 494 patients were female and 272 (55%) were male. The mean age in the total study population was 64·0 years (SD 9·80). Most patients were White (409 [83%] of 494), Asian (61 [12%]), or Black or African American (20 [4%]). Patients in both groups had stable mean EORTC QLQ-C30 and QLQ-MY20 scores over time. At each timepoint, most patients reported stable or improved scores in the global health status/quality of life (64 [56%] of 115 patients to 85 [75%] of 114 patients in the belantamab mafodotin group and 105 [51%] of 207 patients to 156 [65%] of 240 patients in the daratumumab group), role functioning (103 [53%] of 196 patients to 77 [68%] of 114 patients in the belantamab mafodotin group and 99 [50%] of 197 patients to 92 [69%] of 134 patients in the daratumumab group), and physical functioning domains (132 [66%] of 201 patients to 101 [77%] of 131 patients in the belantamab mafodotin group and 115 [58%] of 197 patients to 102 [76%] of 134 patients in the daratumumab group) of the EORTC QLQ-C30 and of the disease symptom domain scores of the EORTC QLQ-MY20 (79 [72%] of 109 patients to 95 [83%] of 115 patients in the belantamab mafodotin group and 126 [66%] of 190 patients to 164 [74%] of 221 patients in the daratumumab group). Most patients in the belantamab mafodotin group (155 [77%] of 202 to 79 [96%] of 82) and the daratumumab group (155 [86%] of 181 to 60 [100%] of 60) reported being "not at all," "a little," or "somewhat" bothered by treatment side-effects at each visit, as determined by the FACT-GP5. INTERPRETATION: HRQOL was generally maintained or improved over time with belantamab mafodotin, bortezomib, and dexamethasone treatment. Our findings, in conjunction with previously reported clinical benefits, support the use of belantamab mafodotin as a potential new standard of care in relapsed or refractory multiple myeloma. FUNDING: GSK. TRANSLATIONS: For the Polish and Spanish translations of the abstract see Supplementary Materials section.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Hungria V, Hus M, Fu C, et al. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. Lancet Haematol. 2025. PMID: 40680752. doi:10.1016/S2352-3026(25)00163-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。